617 related articles for article (PubMed ID: 32942671)
1. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA; Wagstaff KM
Cells; 2020 Sep; 9(9):. PubMed ID: 32942671
[TBL] [Abstract][Full Text] [Related]
2. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA; Wagstaff KM
Biochem Biophys Res Commun; 2021 Jan; 538():163-172. PubMed ID: 33341233
[TBL] [Abstract][Full Text] [Related]
3. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target.
Yuan S; Chu H; Huang J; Zhao X; Ye ZW; Lai PM; Wen L; Cai JP; Mo Y; Cao J; Liang R; Poon VK; Sze KH; Zhou J; To KK; Chen Z; Chen H; Jin DY; Chan JF; Yuen KY
Sci Adv; 2020 Aug; 6(35):eaba7910. PubMed ID: 32923629
[TBL] [Abstract][Full Text] [Related]
4. Antivirals that target the host IMPα/β1-virus interface.
Martin AJ; Jans DA
Biochem Soc Trans; 2021 Feb; 49(1):281-295. PubMed ID: 33439253
[TBL] [Abstract][Full Text] [Related]
5. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer.
Yang SNY; Atkinson SC; Wang C; Lee A; Bogoyevitch MA; Borg NA; Jans DA
Antiviral Res; 2020 May; 177():104760. PubMed ID: 32135219
[TBL] [Abstract][Full Text] [Related]
6. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
[TBL] [Abstract][Full Text] [Related]
7. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
[TBL] [Abstract][Full Text] [Related]
9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
10. Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action.
Rizzo E
Naunyn Schmiedebergs Arch Pharmacol; 2020 Jul; 393(7):1153-1156. PubMed ID: 32462282
[TBL] [Abstract][Full Text] [Related]
11. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
Kato F; Matsuyama S; Kawase M; Hishiki T; Katoh H; Takeda M
Microbiol Immunol; 2020 Sep; 64(9):635-639. PubMed ID: 32579258
[TBL] [Abstract][Full Text] [Related]
13. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
14. The Battle against COVID 19 Pandemic: What we Need to Know Before we "Test Fire" Ivermectin.
Banerjee K; Nandy M; Dalai CK; Ahmed SN
Drug Res (Stuttg); 2020 Aug; 70(8):337-340. PubMed ID: 32559771
[TBL] [Abstract][Full Text] [Related]
15. Lithium for the 2019 novel coronavirus.
Gómez-Bernal G
Med Hypotheses; 2020 Sep; 142():109822. PubMed ID: 32408073
[No Abstract] [Full Text] [Related]
16. HIV and SARS-CoV-2: points to consider to face this new pandemic.
Prieto Pozo AA; Salvador Sagüez FLD
Medwave; 2020 Oct; 20(9):e8049. PubMed ID: 33141814
[TBL] [Abstract][Full Text] [Related]
17. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen.
Heidary F; Gharebaghi R
J Antibiot (Tokyo); 2020 Sep; 73(9):593-602. PubMed ID: 32533071
[TBL] [Abstract][Full Text] [Related]
18. Direct Activation of Adenosine Monophosphate-Activated Protein Kinase (AMPK) by PF-06409577 Inhibits Flavivirus Infection through Modification of Host Cell Lipid Metabolism.
Jiménez de Oya N; Blázquez AB; Casas J; Saiz JC; Martín-Acebes MA
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712653
[TBL] [Abstract][Full Text] [Related]
19. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
[TBL] [Abstract][Full Text] [Related]
20. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
Xu J; Shi PY; Li H; Zhou J
ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
